As of 2026-08-03, the EV/EBITDA ratio of Sigilon Therapeutics, Inc. (SGTX) is -0.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGTX's latest enterprise value is 32.33 mil USD. SGTX's TTM EBITDA according to its financial statements is -34.77 mil USD. Dividing these 2 quantities gives us the above SGTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 16.9x | 14.8x |
| Forward P/E multiples | 15.7x - 17.0x | 15.8x |
| Fair Price | (206.90) - (224.59) | (201.92) |
| Upside | -1020.8% - -1099.5% | -998.6% |
| Date | EV/EBITDA |